Research Progress of the Resistance Mechanism of Non-small Cell Lung Cancer to EGFR-TKIs
10.3779/j.issn.1009-3419.2013.10.07
- VernacularTitle:EGFR-TKI在非小细胞肺癌中耐药机制的研究进展
- Author:
LIU HUIHUI
1
;
WANG MENGZHAO
;
HU KE
;
XU YAN
;
MA MANJIAO
;
ZHONG WEI
;
ZHAO JING
;
LI LONGYUN
;
WANG HUAZHU
Author Information
1. 中国医学科学院北京协和医院呼吸内科
- Keywords:
Lung neoplasms;
EGFR;
EGFR-TKIs;
Resistance
- From:
Chinese Journal of Lung Cancer
2013;(10):535-540
- CountryChina
- Language:Chinese
-
Abstract:
Nowadays, lung cancer is the malignant tumor of the highest morbidity and mortality over the world, and non-small cell lung cancer (NSCLC) makes up about 80%. hTere is a great many NSCLC patients have been in advanced stage when diagnosed. As a result, people pay more attention to curing advanced NSCLC. hTe standard treatment to advanced NSCLC is platinum-based combined chemotherapy. However, chemotherapy drugs usually have limited effects on improving the survival of the patients. hTen exploring new therapies is extremely urgent to us. Now, molecular targeted therapy has been the most promising research area for the treatment of NSCLC with researches going deep into pathogenesis and biological behavior of lung cancer. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have achieved a great suc-cess in the treatment of advanced NSCLC. hTeir representatives are erlotinib and geiftinib. hTe two drugs have been widely used to treat advanced NSCLCs worldwide, especially for the patients with EGFR activating mutations. However, atfer a period of treatment (median time is 6 to 12 months), most patients will develop drug resistance to EGFR-TKIs. Intense research in these NSCLCs has identiifed two major mechanisms of resistance to TKIs:primary and acquired resistances. hTe research about resistance mechanism of NSCLC to EGFR-TKIs is a hot one because of their excellent effects on improving overall and progression-free survival. hTe aim of this article was to summarize the development of the resistance mechanisms.
